Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling
作者： Xin He , Yu Wang , Jinhong Zhu , Mohammed Orloff , Charis Eng
DOI: 10.1016/J.CANLET.2010.11.012
关键词:
摘要: … Because rapamycin is an inhibitor of p70S6K, we then investigated p70S6K and its … Resveratrol slightly suppressed both mTOR and p70S6K phosphorylation in wildtype PTEN …
elsevier.com
sci-hub.se 参考文章(37)
Sheng-Li Wu, Effect of resveratrol and in combination with 5-FU on murine liver cancer World Journal of Gastroenterology. ,vol. 10, pp. 3048- 3052 ,(2004) , 10.3748/WJG.V10.I20.3048
Daniel Lantvit, Rajendra G. Mehta, Richard C. Moon, John M. Pezzuto, Konstantin Christov, Krishna P. L. Bhat, Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models Cancer Research. ,vol. 61, pp. 7456- 7463 ,(2001)
Y Wang, M Mikhailova, S Bose, C-X Pan, R W deVere White, P M Ghosh, Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival Oncogene. ,vol. 27, pp. 7106- 7117 ,(2008) , 10.1038/ONC.2008.318
Oxana Komina, Józefa Węsierska-Gądek, Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells. Biochemical Pharmacology. ,vol. 76, pp. 1554- 1562 ,(2008) , 10.1016/J.BCP.2008.08.002
J B Easton, P J Houghton, mTOR and cancer therapy. Oncogene. ,vol. 25, pp. 6436- 6446 ,(2006) , 10.1038/SJ.ONC.1209886
Erwan Pencreach, Eric Guérin, Céline Nicolet, Isabelle Lelong-Rebel, Anne-Claire Voegeli, Pierre Oudet, Annette K. Larsen, Marie-Pierre Gaub, Dominique Guenot, Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis Clinical Cancer Research. ,vol. 15, pp. 1297- 1307 ,(2009) , 10.1158/1078-0432.CCR-08-0889
Wieslawa H. Dragowska, Maïté Verreault, Donald T. T. Yapp, Corinna Warburton, Lincoln Edwards, Euan C. Ramsay, Lynsey A. Huxham, Andrew I. Minchinton, Karen Gelmon, Marcel B. Bally, Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Research and Treatment. ,vol. 106, pp. 319- 331 ,(2007) , 10.1007/S10549-007-9502-2
John B. Easton, Raushan T. Kurmasheva, Peter J. Houghton, IRS-1: Auditing the effectiveness of mTOR inhibitors Cancer Cell. ,vol. 9, pp. 153- 155 ,(2006) , 10.1016/J.CCR.2006.02.027
X Wan, B Harkavy, N Shen, P Grohar, L J Helman, Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. ,vol. 26, pp. 1932- 1940 ,(2007) , 10.1038/SJ.ONC.1209990
Morris E Feldman, Beth Apsel, Aino Uotila, Robbie Loewith, Zachary A Knight, Davide Ruggero, Kevan M Shokat, Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLOS Biology. ,vol. 7, pp. 0371- 0383 ,(2009) , 10.1371/JOURNAL.PBIO.1000038